Strata Critical Medical, Inc. SRTA

About Strata Critical Medical, Inc. (SRTA): stock profile, AI score and financials

Strata Critical Medical, Inc. (SRTA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRTA at 41.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,054 of 2,925 stocks — the bottom half of the AI-ranked universe. SRTA scores in the top quartile across balance sheet strength (91.5), profitability (79.8). Areas of concern include institutional flow (8.5) and free cash flow (13.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 16.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Strata Critical Medical, Inc. reports quarterly revenue of $72.5M, net income of $-10.5M, an operating margin of -7.5%. Top institutional holders of SRTA by reported 13-F value include Third Point, Northern Right Capital Management, L.P., BlackRock, based on the most recent SEC filings. SRTA trades on the Nasdaq exchange and files with the SEC under CIK 1779128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Strata Critical Medical, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1779128 →